Malaria RDTs
Malaria
CommercialActive
Key Facts
About Access Bio
Access Bio is a commercial-stage diagnostics company with a 20+ year history focused on combating infectious diseases in global health settings. It successfully leveraged its IVD platform to become a significant player in the COVID-19 response, securing multiple FDA Emergency Use Authorizations (EUAs) for antigen, antibody, and molecular tests under its CareStart™ brand. While COVID-19 products were a major recent focus, the company's core expertise and legacy are in malaria and other serious tropical diseases, supplying tests to organizations in low-resource regions. The company appears to have a public listing via Korean Depository Receipts (KDRs), indicating a complex corporate structure with operations in the US and South Korea.
View full company profileTherapeutic Areas
Other Malaria Drugs
| Drug | Company | Phase |
|---|---|---|
| Vaxine Malaria Vaccine | Vaxine | Preclinical |
| Malaria Vaccine | VLP Biotech | Pre-clinical |
| Malaria-on-a-Chip Model | Hesperos | Pre-clinical |
| Malaria Antibodies | new/era/mabs | Research/Pre-clinical |
| Dendritic Cell Vaccine | MegaNano BioTech | Pre-clinical |
| Malaria | Keltic Pharma Therapeutics | Pre-clinical |
| Antibody Programs (Malaria) | Ibex Biosciences | Pre-clinical |
| Malaria Nanobody | VicuTec Biologicals | Pre-clinical |